Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trialH. Miles Prince, M. D’Incan, Oleg E. Akilov et al.|The Lancet|2017Cited by 580
Cutaneous T cell lymphomaReinhard Dummer, Egle Ramelyte, Maarten H. Vermeer et al.|Nature Reviews Disease Primers|2021Cited by 170
Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTCElise A. Olsen, Julia Scarisbrick, Sean Whittaker et al.|Blood|2021Cited by 170
Evaluation of the Long-Term Tolerability and Clinical Benefit of Vorinostat in Patients With Advanced Cutaneous T-Cell LymphomaMadeleine Duvic, Larisa J. Geskin, Elise A. Olsen et al.|Clinical Lymphoma & Myeloma|2009Cited by 97
Pediatric primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder: A retrospective analysis and review of the literatureOluwaseyi Adeuyan, Alejandro A. Gru, Celine M. Schreidah et al.|Journal of the American Academy of Dermatology|2025Cited by 3